Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.030 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Gapping stocks in Monday's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic
CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus. 
Via Stocktwits
Exposures Product Safety
Curious about the stocks that are showing activity after the closing bell on Wednesday?
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Via Benzinga
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
Via Benzinga
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q2 2024
FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Where Fate Therapeutics Stands With Analysts
Via Benzinga
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
Via Benzinga
Recap: Fate Therapeutics Q4 Earnings
Via Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024
FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
A Preview Of Fate Therapeutics's Earnings
Via Benzinga
Analyst Ratings for Fate Therapeutics
Via Benzinga
Recap: Fate Therapeutics Q3 Earnings
Via Benzinga
Analyst Ratings for Fate Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock
Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%. 
Via InvestorPlace
Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Latest Analyst Ratings for Fate Therapeutics
Via Benzinga
Earnings Scheduled For February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 46 stocks hit new 52-week lows. 
Via Benzinga
Why Shares of Fate Therapeutics Soared This Week
The company's shares bounced back after a stock sale last week. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.